An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR

A Target‐Mediated Drug Disposition Population Pharmacokinetic Model of GC1118, a Novel Anti‐EGFR Antibody, in Patients with Solid Tumors

Clinical and Translational Science ◽

10.1111/cts.12963 ◽

2020 ◽

Author(s):

Tae Kyu Chung ◽

Hyun A Lee ◽

Sang‐In Park ◽

Do‐Youn Oh ◽

Keun‐Wook Lee ◽

...

Keyword(s):

Solid Tumors ◽

Population Pharmacokinetic Model ◽

Pharmacokinetic Model ◽

Drug Disposition ◽

Population Pharmacokinetic ◽

Target Mediated Drug Disposition ◽

Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-017-3284-y ◽

2017 ◽

Vol 79 (5) ◽

pp. 915-922 ◽

Cited By ~ 2

Author(s):

Wijith P. Munasinghe ◽

Rajendar K. Mittapalli ◽

Hong Li ◽

David M. Hoffman ◽

Kyle D. Holen ◽

...

Keyword(s):

Solid Tumors ◽

Qt Interval ◽

Advanced Solid Tumors ◽

Interval Prolongation ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Qt Interval Prolongation ◽

Antibody Drug ◽

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR

Investigational New Drugs ◽

10.1007/s10637-020-00908-3 ◽

2020 ◽

Vol 38 (5) ◽

pp. 1483-1494 ◽

Cited By ~ 1

Author(s):

James M. Cleary ◽

Emiliano Calvo ◽

Victor Moreno ◽

Dejan Juric ◽

Geoffrey I. Shapiro ◽

...

Keyword(s):

Solid Tumors ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Drug Conjugate ◽

Antibody Drug ◽

Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors

10.1158/1535-7163.targ-19-a088 ◽

2019 ◽

Author(s):

Jason Melear ◽

Nehal Lakhani ◽

Joyce A O'Shaughnessy ◽

Sharon T Wilks ◽

Saad Khan ◽

...

Keyword(s):

Solid Tumors ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Antibody Drug ◽

28LBA A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(16)31946-3 ◽

2015 ◽

Vol 51 ◽

pp. S724 ◽

Cited By ~ 2

Author(s):

A.W. Tolcher ◽

E. Calvo ◽

M.L. Maitland ◽

B. Gibson ◽

D. Xuan ◽

...

Keyword(s):

Solid Tumors ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Phase 1 Study ◽

Drug Conjugate ◽

Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors

Drugs of Today ◽

10.1358/dot.2019.55.9.3039669 ◽

2019 ◽

Vol 55 (9) ◽

pp. 575 ◽

Cited By ~ 3

Author(s):

K.M. Fenn ◽

K. Kalinsky

Keyword(s):

Breast Cancer ◽

Solid Tumors ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3757 ◽

2021 ◽

pp. clincanres.3757.2020

Author(s):

Michael L. Maitland ◽

Jasgit C Sachdev ◽

Manish R Sharma ◽

Victor Moreno ◽

Valentina Boni ◽

...

Keyword(s):

Tyrosine Kinase ◽

Solid Tumors ◽

Protein Tyrosine Kinase ◽

Human Study ◽

Advanced Solid Tumors ◽

Antibody Drug Conjugate ◽

Protein Tyrosine ◽

Drug Conjugate ◽

Protein Tyrosine Kinase 7 ◽

Integrated Two‐Analyte Population Pharmacokinetic Model for Antibody–Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling

CPT Pharmacometrics & Systems Pharmacology ◽

10.1002/psp4.12137 ◽

2016 ◽

Vol 5 (12) ◽

pp. 665-673 ◽

Cited By ~ 4

Author(s):

D Lu ◽

L Gibiansky ◽

P Agarwal ◽

RC Dere ◽

C Li ◽

...

Keyword(s):

Population Pharmacokinetic Model ◽

Pharmacokinetic Model ◽

Population Pharmacokinetic ◽

Antibody Drug Conjugates ◽

Drug Conjugates ◽

Abstract 1197: Outstanding preclinical efficacy of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 in patient-derived xenograft solid tumors

10.1158/1538-7445.am2016-1197 ◽

2016 ◽

Cited By ~ 1

Author(s):

Loreley Calvet ◽

Anne-Marie Lefebvre ◽

Celine Nicolazzi ◽

Lydia Blot ◽

Corinne Thomas ◽

...

Keyword(s):

Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Patient Derived Xenograft ◽

Preclinical Efficacy ◽

Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors

10.1158/1538-7445.am2017-52 ◽

2017 ◽

Author(s):

Francesca Zammarchi ◽

Halla W. Reinert ◽

Narinder Janghra ◽

Simon Corbett ◽

Maria Mellinas-Gomez ◽

...

Keyword(s):

Solid Tumors ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽